Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Market OverviewThe Global Generic Drugs Market was valued at $411.99 Billion in 2022 and is projected to reach $613.34 ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Allied Market Research published a report, titled, "Serum Free and Specialty Media Market by Product (CHO Media, HEK Media, Hybridoma Media, and Others), Application (Biopharmaceutical Production, ...